Dark

Check out our API

AXGT
Axovant Gene Therapies Ltd. Common Shares
stock NASDAQ

Inactive

Nov 12, 2020

2.10USD-2.326%(-0.05)490,911

Pre-market

0.00USD0.000%(0.00)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Dec 2, 2020

07:00AM EST -- On-track toreport topline results from low-dose cohort by end of 2020 GlobeNewswire Inc

Nov 30, 2020

09:38PM EST Pomerantz LLP is investigating claims on behalf of investors ofSio Gene Therapies, Inc.(Sio or the Company) (NASDAQ: AXGT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Nov 25, 2020

10:02PM EST Pomerantz LLP is investigating claims on behalf of investors of Axovant Gene Therapies Ltd. (Axovant or the Company) (NASDAQ: AXGT). Such investors are advised to contact Robert S. Willoughby atnewaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Nov 19, 2020

08:00AM EST -- A pioneering researcher, Dr. Gao has made foundational contributions to the discovery of novelAAVvectors for gene therapy -- Dr. Gao recently served as President of the American Society for Gene and Cell Therapy (ASGCT) and has been rankedas one of the top 20 translational researchers by Nature Biotechnology GlobeNewswire Inc

Nov 16, 2020

09:33PM EST Pomerantz LLP is investigating claims on behalf of investors of Axovant Gene Therapies Ltd. (Axovant or the Company) (NASDAQ: AXGT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Nov 13, 2020

07:00AM EST Sio Gene Therapies Announces Corporate Updates and Financial GlobeNewswire Inc

Nov 10, 2020

07:00AM EST -- Rebranding to Sio Gene Therapies to reflect an independent company with a scientific strategy focused on disease-modifying and curative genetic medicines -- Companys common stock will trade on the NASDAQ under new ticker SIOX effective November 13, 2020 GlobeNewswire Inc

Nov 9, 2020

07:11AM EST Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases Benzinga

07:11AM EST Axovant Gene Therapies: FDA Clears IND Application To Begin Registrational Study Of AXO-AAV-GM2 Gene Therapy RTTNews

07:00AM EST -- AXO-AAV-GM2 is the first investigational gene therapy to receive IND clearance in Tay-Sachs and Sandhoff diseases -- Represents Axovants second IND clearance for a gene therapy program in the last 12 months GlobeNewswire Inc

Oct 30, 2020

03:15PM EDT Mid-Afternoon Market Update: Rogers Jumps Following Upbeat Q3 Results; Pitney Bowes Shares Plunge Benzinga

12:08PM EDT Mid-Day Market Update: Nasdaq Tumbles Over 300 Points; Acadia Healthcare Shares Gain After Q3 Results Benzinga

10:18AM EDT Mid-Morning Market Update: Markets Open Lower; Honeywell Earnings Beat Estimates Benzinga

08:09AM EDT The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts Benzinga

Oct 29, 2020

04:15PM EDT Axovant Gene Therapies To Present AXO-Lenti-PD Program Update During Virtual Parkinson's Disease R&D Day On October 30, 2020 Benzinga

Oct 22, 2020

07:00AM EDT -- Agenda to feature presentations from leading clinical researchers in Parkinsons disease and the Michael J. Fox Foundation -- Individual patient-level data from Cohort 2 of the Phase 2 SUNRISE-PD study to be shared GlobeNewswire Inc

Oct 13, 2020

08:30AM EDT Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Oct. 13, 2020: AAPL, DAL, RPLA, FOUR, AXGT Benzinga

07:17AM EDT Axovant Gene Therapies Receives Rare Pediatric Disease Designation From FDA For AXO-AAV-GM2 RTTNews

07:08AM EDT Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM2 for Tay-Sachs and Sandhoff Disease Benzinga

07:00AM EDT Axovant Gene Therapies Receives Rare Pediatric Disease Designation GlobeNewswire Inc

Oct 9, 2020

07:20AM EDT Axovant Gene Therapies Ltd. (AXGT) said Friday that it has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for AXO-AAV-GM1. It is an AAV9-based gene therapy delivered through a single intravenous administration that is in Phase 1/2 development for GM1 gangliosidosis. RTTNews

07:05AM EDT Axovant Gets Rare Pediatric Disease Designation For AXO-AAV-GM1 For GM1 Gangliosidosis RTTNews

07:01AM EDT Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 Gangliosidosis Benzinga

07:00AM EDT Axovant Gene Therapies Receives Rare Pediatric Disease Designation GlobeNewswire Inc

Oct 8, 2020

07:00AM EDT Axovant Gene Therapies Strengthens Board of Directors and GlobeNewswire Inc

Oct 6, 2020

02:34PM EDT Mid-Afternoon Market Update: Dow Surges 150 Points; Alteryx Shares Spike Higher Benzinga

02:30PM EDT Why Axovant's Stock Is Trading Lower Today Benzinga

12:32PM EDT Mid-Day Market Update: Crude Oil Rises Over 3%; Miragen Therapeutics Shares Slide Benzinga

10:15AM EDT Mid-Morning Market Update: Markets Rise; Paychex Beats Q1 Views Benzinga

07:03AM EDT Axovant Announces Positive Six-Month Follow-Up Data From Second Cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD Gene Therapy Benzinga

07:00AM EDT Axovant Announces Positive Six-Month Follow-Up Data From Second GlobeNewswire Inc

Oct 5, 2020

10:51AM EDT Shares of Axovant Gene Therapies Ltd. (AXGT) are climbing more than 15% Monday morning at $5.25. It has been trading in the range of $1.41- $6.93 in the last one year. RTTNews

07:00AM EDT Axovant to Participate in Upcoming October Conferences and Provide GlobeNewswire Inc

Sep 15, 2020

08:08AM EDT Axovant Gene Therapies Reports Development, Manufacturing Partnership With Viralgen Benzinga

08:01AM EDT -- Partnership secures access to cGMP capacity and resources at Viralgen to support the development and commercialization of Axovants AAV gene therapy programs for GM1 and GM2 gangliosidosis -- Partnership bolsters the Companys clinical and commercial capacity and expands access to process development, analytical development, and manufacturing expertise GlobeNewswire Inc

Sep 8, 2020

07:30AM EDT -Parkinsons Disease R&D Day to be hosted by Gavin Corcoran, MD, Chief R&D Officer, on October 30th, 2020, with leading movement disorder specialists GlobeNewswire Inc

Aug 11, 2020

07:20AM EDT Axovant Gene Therapies Q1 EPS $(0.20) Up From $(1.23) YoY Benzinga

07:00AM EDT -- Data readouts for AXO-Lenti-PD and AXO-AAV-GM1 remain on-track for Q4 2020 -- Completed 3-year manufacturing and supply agreement with Oxford BioMedica for AXO-Lenti-PD -- Company had $55.5 million of cash and cash equivalents as of June 30, 2020 GlobeNewswire Inc

Jul 31, 2020

02:03PM EDT Axovant Gene Therapies shares are trading higher after the company announced it has signed a 3-year deal with Oxford Biomedica for manufacturing and supplying AXO-Lenti-PD. Benzinga

07:38AM EDT Oxford Biomedica Signs Three Year Clinical Supply Agreement With Axovant Gene Therapies For Manufacture And Supply Of AXO-Lenti-PD Benzinga

06:38AM EDT Axovant Gene Therapies Reports 3-Year Clinical Supply Deal With Oxford Biomedica For Manufacturing, Supply Of AXO-Lenti-PD, No Terms Disclosed Benzinga

06:30AM EDT Axovant Signs Three-Year Clinical Supply Agreement With Oxford GlobeNewswire Inc

Share